Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tanox. (TNOX) -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (2)	9/15/2000 7:03:30 PM
From: Barron Von Hymen	Respond to of 10

I'm not certain you can identify with certainty that their drug caused lowered platelet counts. Toxicology data is not impressive. After all the doses that killed the monkey were an order of magnitude greater than the max clinical dose. What is of concern is that Novartis has pulled the plug on new enrollments into clinical trials. What this means is uncertain, since it is not clear that the halt is related directly to the new toxicology data, and what exact reasons they have for doing so. Information we're not likely to get.

To: Don Miller who wrote (2)	9/15/2000 7:03:43 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 10

I'm not certain you can identify with certainty that their drug caused lowered platelet counts. Toxicology data is not impressive. After all the doses that killed the monkey were an order of magnitude greater than the max clinical dose. What is of concern is that Novartis has pulled the plug on new enrollments into clinical trials. What this means is uncertain, since it is not clear that the halt is related directly to the new toxicology data, and what exact reasons they have for doing so. Information we're not likely to get. I thought TNOX would fall much more today on the news.